Sign in

    Colleen Cousy • Baird

    Colleen Kusy is a Vice President and Senior Equity Research Analyst at Baird specializing in biotechnology sector research with an emphasis on smid-cap companies, oncology, and rare diseases. Since joining Baird in 2014, she has developed expertise in evaluating diverse therapeutic areas and is recognized for her coverage of leading firms in the retinal treatment space, with a reputation for effective communication of investment insights. In 2023, she was named a 'Rising Star of Equity Research' by Business Insider for her impact on the industry, having progressed from a business analyst to her current senior leadership role. Kusy holds a CFA designation and earned a BBA in Finance as well as a BA in French and Francophone Studies from Villanova University.

    Colleen Cousy's questions to Mersana Therapeutics Inc (MRSN) leadership

    Colleen Cousy's questions to Mersana Therapeutics Inc (MRSN) leadership • Q2 2025

    Question

    An analyst on behalf of Colleen Cousy at Baird asked about the enrollment rate for EMILY compared to internal expectations and also inquired about the enrollment progress for the HER2-targeting ADC, XMT-2056.

    Answer

    President and CEO Dr. Martin Huber expressed that EMILY enrollment is progressing 'very well' for a biomarker-selected study and that no additional sites are needed for the expansion phase. For XMT-2056, he pointed to the recent $15 million development milestone from GSK as evidence that enrollment has picked up and the program is 'chugging along,' while reiterating that the company is not committing to sharing dose-escalation data this year.

    Ask Fintool Equity Research AI